FDA Grants Accelerated Approval to Zanidatamab-hrii for Patients with Previously Treated Unresectable or Metastatic HER2-positive Biliary Tract Cancer By Ogkologos - December 17, 2024 298 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the HERIZON-BTC-01 study Source RELATED ARTICLESMORE FROM AUTHOR Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe EMA Recommends Extension of Therapeutic Indications for Ponatinib Screening Programme by Primary Colonoscopy or Two Rounds of Two-Stool FIT Detects More Lower-Stage CRCs than Usual Care MOST POPULAR Better EFS Outcomes with Perioperative Durvalumab Plus FLOT Than with Placebo... June 10, 2025 Cancer Patient Dresses Up To Cheer Others In Chemo & The... March 18, 2019 Suzanne Somers Discusses Her Cancer Diagnosis And Thinking Of Her ‘Mortality’ January 6, 2020 New on NCI’s Websites for December 2023 December 28, 2023 Load more HOT NEWS Only a Quarter of Phase III Studies Demonstrated Improved QoL in... Helping Dogs—and Humans—with Cancer: NCI’s Comparative Oncology Studies Regular Exercise May Boost Immune Response and Improve Immunotherapy in Breast... Tackling under-representation of Black data scientists in cancer research
